about
Drug discovery prospect from untapped species: indications from approved natural product drugsThe Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network PerspectiveExploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics StudyPerformance Evaluation and Online Realization of Data-driven Normalization Methods Used in LC/MS based Untargeted Metabolomics Analysis.Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells.NOREVA: normalization and evaluation of MS-based metabolomics data.What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical, and systems profiles of successful targets.Update of PROFEAT: a web server for computing structural and physicochemical features of proteins and peptides from amino acid sequenceTherapeutic target database update 2012: a resource for facilitating target-oriented drug discovery.Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods.SVM-Prot 2016: A Web-Server for Machine Learning Prediction of Protein Functional Families from Sequence Irrespective of Similarity.Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information.Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness.Therapeutic target database update 2014: a resource for targeted therapeutics.Recent progresses in the exploration of machine learning methods as in-silico ADME prediction tools.Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs.Evidence for possible role of toll-like receptor 3 mediating virus-induced progression of pituitary adenomas.A protein network descriptor server and its use in studying protein, disease, metabolic and drug targeted networks.How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks.Prediction of factor Xa inhibitors by machine learning methods.Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation.Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics.Assessing the Performances of Protein Function Prediction Algorithms from the Perspectives of Identification Accuracy and False Discovery Rate.HawkRank: a new scoring function for protein-protein docking based on weighted energy terms.What Contributes to Serotonin-Norepinephrine Reuptake Inhibitors' Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation.Differentiating Physicochemical Properties between Addictive and Nonaddictive ADHD Drugs Revealed by Molecular Dynamics Simulation Studies.Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder.Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD.Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK.Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study.Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease through Comparative Structure-Based Virtual Screening.Clinical Success of Drug Targets Prospectively Predicted by In Silico Study.Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder.Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations.PROFEAT Update: A Protein Features Web Server with Added Facility to Compute Network Descriptors for Studying Omics-Derived Networks.A resource for facilitating the development of tools in the education and implementation of genomics-informed personalized medicine.Nature's contribution to today's pharmacopeia.Assessing the performance of MM/PBSA and MM/GBSA methods. 8. Predicting binding free energies and poses of protein-RNA complexesRecent Advances and Challenges of the Drugs Acting on Monoamine Transporters
P50
Q28481257-8FE91DF4-4FEF-4691-8DD5-006F20F151DBQ28553277-63B77A2E-0987-48B0-926A-DC63C6BA2F05Q28833274-F6D78EFC-ABAA-47BE-8655-CD199D583352Q31148475-88099402-0EEB-41CE-ADC9-8C21DA56B7CEQ33914014-7E853D84-6955-4008-B59E-9F9745B78DC9Q34556970-6F94B6B7-C438-4C19-9FA7-70C7A7410F7BQ34974858-48E4DF7A-D2C7-499B-BF0D-796DF2EBCB0CQ35075527-FD4D46BE-4EB3-4426-AF92-5FEB8927577AQ35631111-26C6E7B7-D91A-46E1-97AD-91944AE827F3Q35787663-4F52822E-C3CF-4032-8358-0D705C0829FEQ36104137-60705B89-967C-4F89-94A5-56A6295DE0BFQ36434850-BECC98CA-45B6-4C18-83D0-623C1BF21C01Q36774606-ADEFA9E5-4B56-4F5A-8F12-96A38D6E93BCQ37661746-181A6B94-3712-4C1C-91FC-B16F094A5CA4Q38513539-FC1CB86B-7E82-4864-A792-503487D43B7EQ38599876-C438D57D-6786-47CD-A193-E0F304FDFD57Q38792923-C79DCC2C-CDD5-4168-A9EF-035D41AE9163Q39472758-37D9DEB3-F6F2-4D3F-90FA-588575EB36A2Q41490661-52EFC126-A0D1-4C48-A5B3-C5C5F8332F3AQ42195551-7FACCBCD-4ADC-4CDF-97A5-3FCE0D7FE5A1Q45965422-102460D4-E16B-4A6B-8281-DADC49C71597Q47094795-B7D948D0-2668-48B2-9B95-460D1E999776Q47116549-8C59DFE7-3EC3-41A1-8863-407AE9D56B98Q47216858-745886A9-D53C-4805-B181-EDFF86F0D28FQ47250694-6A1A2BCF-73F6-43DF-9868-9CBDDB69E59AQ47664189-B7FE54C5-1DDF-4F67-A584-4AF1243D6A45Q47709788-1B0AF4B0-67F6-45A3-B147-D205504F829CQ47732078-56BDC12F-9A61-467E-B133-CFF88B081E34Q47865254-3AEB1FE6-3B5D-4C6D-9AC9-20077EA45EECQ48042996-232B85C9-7D9A-496A-9F03-D231C56D4F92Q48066819-503D809C-2D4B-4D30-98E1-84D785472E75Q48207825-6602992C-4EC6-436A-9D15-AAE7FEDDC7BDQ49360899-29D71D80-4156-49C1-BDE4-4B6A96567A85Q49937906-D860288A-1474-4EE8-BEB7-836DE80EDFFEQ50531567-E1B9ACC4-61D4-4534-BD11-7BA9CD6A1C47Q51121746-128C22DD-639D-422D-B332-CB388C5CD1CDQ51591754-EA23D794-B138-45F9-BC14-21582022F18EQ53419688-042C9F96-724A-48FE-90A7-77833D92CAE9Q57120322-DCB7BF29-5094-40FC-B2C6-B5ACD0E4C015Q57288343-CEF190D0-8189-418D-9954-783E1DE8788D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Feng Zhu
@ast
Feng Zhu
@en
Feng Zhu
@es
Feng Zhu
@sl
type
label
Feng Zhu
@ast
Feng Zhu
@en
Feng Zhu
@es
Feng Zhu
@sl
prefLabel
Feng Zhu
@ast
Feng Zhu
@en
Feng Zhu
@es
Feng Zhu
@sl
P108
P106
P2456
P31
P496
0000-0001-8069-0053